Valuation Ligand Pharmaceuticals Incorporated

Stocks

Real-time Estimate Cboe BZX 10:28:18 2026-10-29 EDT			5-day change	1st Jan Change
322.46 ^USD	+1.16%		+3.94%	+69.23%

10:26am	Ligand Pharmaceuticals Incorporated Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026	CI
08:59am	(LGND) Ligand Pharmaceuticals Expects 2026 Revenue Range $270M - $310M, vs. FactSet Est of $289.5M	MT

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	2,581	1,128	1,245	2,025	3,721	6,355	-	-
Change	-	-56.28%	10.35%	62.59%	83.8%	70.78%	-	-
Enterprise Value (EV)	2,581	1,128	1,245	2,025	3,721	6,355	6,355	6,355
Change	-	-56.28%	10.35%	62.59%	83.8%	70.78%	0%	0%
P/E	46.2x	-33.7x	24.3x	-487x	30.8x	60.5x	37.1x	29.8x
PBR	-	-	-	-	-	-	-	-
PEG	-	0x	-0x	5x	-0x	-4.3x	0.6x	1.2x
Capitalization / Revenue	9.31x	5.75x	9.48x	12.1x	13.9x	22x	16.7x	14.4x
EV / Revenue	0x	0x	0x	0x	0x	22x	16.7x	14.4x
EV / EBITDA	0x	0x	0x	0x	0x	35.5x	22.8x	18.9x
EV / EBIT	0x	0x	0x	-0x	0x	51.9x	27.4x	22.4x
EV / FCF	0x	0x	0x	0x	0x	47.2x	28.7x	25.4x
FCF Yield	2.71%	10.6%	3.7%	4.7%	1.31%	2.12%	3.48%	3.94%
Dividend per Share ²	-	-	-	-	-	-	-	-
Rate of return	-	-	-	-	-	-	-	-
EPS ²	3.34	-1.98	2.94	-0.22	6.13	5.271	8.586	10.71
Distribution rate	-	-	-	-	-	-	-	-
Net sales ¹	277.1	196.2	131.3	167.1	268.1	288.9	381.7	441.8
EBITDA ¹	164.9	87.8	70.29	62.25	136.5	178.8	278.1	336.2
EBIT ¹	78.9	3.037	11.94	-22.61	41	122.6	232	284
Net income ¹	57.59	-33.36	52.15	-4.032	124.5	112.5	187.7	239.6
Net Debt	-	-	-	-	-	-	-	-
Reference price ²	154.46	66.80	71.42	107.15	189.07	318.78	318.78	318.78
Nbr of stocks (in thousands)	16,712	16,894	17,436	18,895	19,682	19,936	-	-
Announcement Date	2/17/22	2/22/23	2/27/24	2/27/25	2/26/26	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (N)	EV / Sales (N)	EV / EBITDA (N)	Dividend Yield (N)	Capi.($)
LIGAND PHARMACEUTICALS INCORPORATED	60.48x	-	-	-.--%	6.36B
ELI LILLY AND COMPANY	37.84x	13.27x	28.43x	0.53%	1,148B
JOHNSON & JOHNSON	39.67x	6.67x	18.75x	1.97%	652B
ABBVIE INC.	37.4x	8.39x	17.35x	2.4%	505B
ROCHE HOLDING AG	21.45x	5.21x	12.93x	2.51%	384B
MERCK & CO., INC.	102.73x	5.76x	24.72x	2.42%	348B
NOVARTIS AG	21.89x	5.76x	13.88x	2.85%	294B
ASTRAZENECA PLC	22.21x	4.49x	12.82x	1.97%	264B
AMGEN INC.	28.66x	7.33x	13.12x	2.23%	244B
GILEAD SCIENCES, INC.	-45.79x	7.11x	27.55x	2.07%	197B
Average	32.65x	7.11x	18.84x	1.9%	404.35B
Weighted average by Cap.	35.32x	8.40x	20.64x	1.79%